Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
– Data demonstrates Notable’s PPMP potential in selecting more active investigational pre-hematopoietic stem cell therapy drug combinations, as compared to regimens currently used in JMML –
FOSTER CITY, Calif., June 09, 2023 (GLOBE NEWSWIRE) — Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today presented data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more active investigational pre-hematopoietic stem cell therapy (pre-HCST) regimens for the treatment of juvenile myelomonocytic leukemia (JMML) at the European Hematology Association (EHA) Hybrid Congress being held in Frankfurt, Germany on June 8 – 15, 2023.
“In collaboration with leading experts at University of California San Francisco, Benioff Children’s Hospital, we screened more than 100 prospective drug combinations on one of the largest collections of primary JMML samples and identified potentially more potent drug combinations for the treatment of JMML than currently used regimens,” said Thomas Bock, M.D., Chief Executive Officer of Notable. “Specifically, this study makes a compelling case for the addition of tretinoin (TRET) to the conventional, but often suboptimal, anti-leukemic combination of fludarabine (FLU) with cytarabine (ARA-C), or 5-azacitidine (5-AZA) alone, and similarly for the addition of calcitriol (CALC) to 5-AZA. Overall, this data provides strong reason to further investigate these potentially more effective drug combinations as there remains a persistent need to develop better pre-HSCT regimens in JMML.”
The study aimed to identify novel anti-leukemic drug combinations potentially more effective than currently used regimens in JMML pre-HSCT by employing Notable’s PPMP. Of 130 drug combinations, 27 were shown to be more active in killing leukemic cells ex vivo than compounds represented in these combinations on their own. In particular, TRET, a differentiating agent, enhanced the anti-leukemic effects of FLU + ARA-C in 90% (19/21) of patient samples and of 5-AZA in 76% (19/25) of patient samples. Similarly, CALC, another differentiating agent, enhanced the anti-leukemic effect of 5-AZA in 84% (21/25) of patient samples.
These results highlight PPMP as a potential tool for identifying superior drug combinations for patients with high medical needs, including with JMML.
Abstract title: Tretinoin and calcitriol enhance treatment regimens for juvenile myelomonocytic leukemia in ex vivo drug sensitivity assays.
Presenting Author: Associate Prof. Elliot Stieglitz
Abstract Code: P998
Session Type/Title: Poster Presentation
Date and Time: June 9, 18:00 – 19:00 CEST
Additional meeting information can be found on the 2023 EHA Congress website, https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/. The poster will be available on the Company’s website at https://notablelabs.com/ shortly after the event.
About Notable Labs, Inc.
Notable Labs, Inc. is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio- simulates a cancer treatment and aims to predict whether or not a patient is likely to respond to that specific therapeutic. Notable’s PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. By continually advancing and expanding the reach of the PPMP across diseases and predicted medical outcomes, Notable aims to be the leader in precision medicine and revolutionize the way in which patients seek and receive treatments that work best for them – patient by patient and cancer by cancer. Notable believes it has created a targeted and de-risked in-licensing strategy to deliver a product’s medical impact and commercial value faster, higher, and with a greater likelihood of success than traditional drug development. By transforming historical standards of care, Notable aims to create dramatic positive impact for patients and the healthcare community. In February 2023, Notable entered into a definitive agreement to merge with VBL Therapeutics (NasdaqCM: VBLT). Notable is headquartered in Foster City, California. Learn more at www.notablelabs.com and follow us @notablelabs.
Investor Relations: Daniel Ferry, LifeSci Advisors
+1 (617) 430-7576, email@example.com